---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-112728"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:24:43.728029+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vyome reports Q3 cash $5.7M; VT-1953 Phase 2 interim hits primary endpoint

## Summary
- VT-1953 Phase 2 interim data: statistically significant malodor reduction (p<0.001); pain and QoL improved; safety profile excellent.
- Cash, equivalents & short-term investments $5.7 million; expected runway through end of 2026 inclusive of clinical trials.
- Net loss primarily from one-time merger/financing non-cash charges; company is pre-revenue clinical stage.
- Clean capital structure: 5,556,295 shares outstanding, no preferred stock, no warrants or convertible notes.
- Acquired MIT startup Oculo to launch AI strategy; hired new CTO and SVP of Clinical Development with Big Pharma backgrounds.

## SEC filing metadata
- accession: 0001213900-25-112728
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000121390025112728/0001213900-25-112728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000121390025112728/ea0266347-8k_vyome.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-112728
- JSON: https://secwatch.observer/filing/0001213900-25-112728.json
- Plain text: https://secwatch.observer/filing/0001213900-25-112728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.